10.08.2025, 840 Zeichen

Valneva: Austrian/French Valneva SE, a specialty vaccine company, today announced that the FDA has removed its recommended pause in the use of IXCHIQ^® in individuals 60 years of age and older and has approved updates to the Prescribing Information (PI) for IXCHIQ^®. IXCHIQ^® remains indicated in the United States for the prevention of disease caused by the Chikungunya Virus (CHIKV) in individuals 18 years of age and older who are at high risk of exposure to CHIKV. The FDA decision follows the announcement in July by the European Medicines Agency (EMA)¹ which recommended the lifting of temporary restrictions in elderly people after the conclusion of a thorough review of IXCHIQ^® by its safety committee (PRAC).
Valneva: weekly performance: 21.47%

(From the 21st Austria weekly https://www.boerse-social.com/21staustria (07/08/2025)

Christian Drastil: Wiener Börse Plausch

D&D Research Rendezvous #22: Gunter Deuber mit Blick auf den ATX, besonderen Blick auf AT&S, dazu Notenbanken, Standort, KI und Treasury

Bildnachweis

Aktien auf dem Radar:AT&S, Lenzing, Strabag, Austriacard Holdings AG, Semperit, EuroTeleSites AG, Erste Group, FACC, Addiko Bank, voestalpine, Rosgix, Fabasoft, Mayr-Melnhof, Agrana, CPI Europe AG, Telekom Austria, BKS Bank Stamm, Wolford, Amag, Österreichische Post, Symrise, Fresenius Medical Care, Fresenius, Rheinmetall, Deutsche Telekom, Brenntag, SAP, Volkswagen Vz., DAIMLER TRUCK HLD..., Deutsche Post, Siemens Healthineers.

---